Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Zenosense, Inc. (OTC: ZENO).

Full DD Report for ZENO

You must become a subscriber to view this report.


Recent News from (OTC: ZENO)

Zenosense, Inc. (ZENO) Attracts Investment Funds for Next Step in Development of MIDS Cardiac Point of Care Diagnostic Device
Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold adv...
Source: NetworkNewsWire
Date: October, 02 2018 11:00
NetworkNewsBreaks - Zenosense, Inc. (ZENO) MML JV Expands Technical Team
Healthcare technology company Zenosense (OTC: ZENO) this morning announced that, in support of the next phase of development of MIDS Cardiac, its MIDS Medical Ltd. (“MML”) joint venture (“JV") has expanded its technical team. MML has engaged three key contractors following...
Source: NetworkNewsWire
Date: October, 02 2018 08:30
Zenosense, Inc.: MIDS Medical Expands Technical Team
VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart a...
Source: GlobeNewswire
Date: October, 02 2018 07:30
NetworkNewsBreaks - Zenosense, Inc. (ZENO) MIDS Cardiac Device Could Spare Patients from Unnecessary Evaluation Expenses
Healthcare technology company Zenosense (OTC: ZENO), a co-owner of the United Kingdom’s MIDS Medical Limited (“MML”) and its innovative handheld MIDS technology, is engaged in the ongoing development of its innovative MIDS Cardiac device. A recent article about the company...
Source: NetworkNewsWire
Date: September, 28 2018 14:30
Zenosense, Inc.'s (ZENO) Heart Attack Testing Technology Development Continues to Advance Hopes of Portable Point of Care Device
Company’s MIDS Cardiac device aims to help ER personnel perform quick, high-sensitivity analysis of heart events MIDS device’s handheld portability is being developed to allow quick-response resource to minimally trained ambulance personnel Final device could ultimately he...
Source: NetworkNewsWire
Date: September, 24 2018 11:15
NetworkNewsBreaks - Zenosense, Inc. (ZENO) MIDS Medical Ltd. JV Secures Up to $1.2M in Staged Funding
Zenosense (OTC: ZENO), a healthcare technology company, this morning announced that its MIDS Medical Ltd. (“MML") joint venture (“JV”) has entered a staged funding for the next phase of development of the MIDS Cardiac™ hand-held technology. MML entered into an agree...
Source: NetworkNewsWire
Date: September, 05 2018 08:30
Innovative Diagnostic Technology Playing Significant Role in Improving Detection for Better Cardiac Care
Palm Beach, FL – (September 5, 2018) – Heart disease is one of the leading causes of death in the western world. In Europe and the U.S. alone, it is estimated 15 to 20 million patients a year visit the emergency departments of hospitals reporting chest pain that could be a sign of ...
Source: FinancialBuzz.com
Date: September, 05 2018 08:13
Zenosense, Inc.: MIDS Medical JV to Receive Funding of Up to $1.2 Million
VALENCIA, SPAIN, Sept. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of hea...
Source: GlobeNewswire
Date: September, 05 2018 07:30
NetworkNewsBreaks - Zenosense, Inc.'s (ZENO) MIDS Cardiac(TM) Uniquely Designed to Provide Lab-Comparable Accuracy in Minutes at Point of Care
Zenosense’s (OTC: ZENO) MIDS Cardiac™ may prove revolutionary in the niche cardiac diagnostic testing market, currently valued between $2 and $6 billion in the U.S. A recent article discussing this, reads “MIDS Cardiac™ is unique, because the technology is being dev...
Source: NetworkNewsWire
Date: August, 24 2018 14:45
MIDS Cardiac by Zenosense, Inc. (ZENO): A Heart Attack Diagnostic Revolution?
The handheld testing device technology under development by Zenosense aims to deliver rapid results and state-of-the-art, laboratory-accurate results for the quick diagnosis of heart attacks Medical professionals believe that diagnosis within 30 minutes of a heart attack is the golden sta...
Source: NetworkNewsWire
Date: August, 15 2018 11:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-100.2480.230.2590.2393,774
2018-12-070.280.240.280.2421,930
2018-12-060.230.240.270.2328,156
2018-12-050.26010.240.26010.2493,524
2018-12-040.26010.240.26010.2493,524

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-072,78021,93012.6767Cover
2018-12-0623,98928,15685.2003Short
2018-12-0463,36893,52467.7559Short
2018-12-038,70029,63829.3542Cover
2018-11-3010,96958,36418.7941Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ZENO.


About Zenosense, Inc. (OTC: ZENO)

Logo for Zenosense, Inc. (OTC: ZENO)

Zenosense Inc. s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost effective, hand held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical Ltd. applies patent protected magnetic nanoparticle detection technology and a development team with world class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers.

 

Contact Information

 

 

Current Management

  • Carlos Jose Gil / President, CEO, CFO
  • Carlos Jose Gil /

Current Share Structure

  • Market Cap: $13,714,669 - 03/09/2018
  • Authorized: 500,000,000 - 02/05/2018
  • Issue and Outstanding: 25,397,536 - 02/05/2018
  • Float: 15,148,692 - 01/29/2018

 


Recent Filings from (OTC: ZENO)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 17 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017

 

 


Daily Technical Chart for (OTC: ZENO)

Daily Technical Chart for (OTC: ZENO)


Stay tuned for daily updates and more on (OTC: ZENO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ZENO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ZENO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ZENO and does not buy, sell, or trade any shares of ZENO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/